Adipogen/Etoposide/AGCR135725100/5 x 100 mg

MoreInformation
ProductDetails
Synonyms	VP-16-213;NSC141540
ProductType	Chemical
Properties
Formula	C₂₉H₃₂O₁₃
MW	588.6
MerckIndex	14:3886
CAS	33419-42-0
RTECS	KC0190000
Source/HostChemicals	Semisyntheticderivativeofpodophyllotoxin.
PurityChemicals	≥98%(HPLC)
Appearance	Whitetooff-whitepowder.
Solubility	SolubleinDMSO,ethanol,methanolordimethylformamide.
InChiKey	VJJPUSNTGOMMGY-MRVIYFEKSA-N
ShippingandHandling
Shipping	AMBIENT
ShortTermStorage	+20°C
LongTermStorage	+20°C
HandlingAdvice	Protectfromlightandmoisture.
Use/Stability	Stableforatleast2yearsafterreceiptwhenstoredat+20°C. StoresolutionsinDMSOat4°C. Afterreconstitution,preparealiquotsandstoreat-20°C.
Documents
MSDS	DownloadPDF
ProductSpecificationSheet
Datasheet	DownloadPDF

Potentanti-cancercompound.Inducesapoptosisinnormalandtumorcelllines[1,5].
DNATopoisomeraseIIactivityinhibitor.IncreasesTopoII-mediatedDNAbreakageprimarilybyinhibitingtheabilityoftheenzymetoreligatecleavednucleicacidmolecules.DoesnotleadtoimmediateblockofDNSsynthesis,inducesaprogressiveinhibitionofDNAreplication[2,4,6].
p53activator[3].
BlocksthecellcyclebetweentheendoftheSphaseandtheearlyG2phase[2,8].
OncoproteinMdm2synthesisinhibitor[7].
Apoptosisinducerthroughthecytochromec/Apaf-1/caspase-9pathwayandtheFas-mediateddeathsignalingpathway[9,10].
Cellcyclecheckpointactivator.Affectsgeneexpressionatdifferentlevels(chromatinremodeling,transcriptionandalternativesplicing)[11,14,15].
Chemotherapeuticcompoundusedincancers[12,13].
Usedinconditioningregimenpriortoabonemarroworbloodstemcelltransplantation[16].
Highlyeffectiveinmobilizingstemcells[17]

ProductReferences

ThepodophyllotoxinderivativesVP16-213andVM26:B.F.Issell;CancerChemother.Pharmacol.7,73(1982)
Topoisomerase-specificdrugsensitivityinrelationtocellcycleprogression:K.C.Chow&W.E.Ross;Mol.Cell.Biol.7,3119(1987)
IncreasesinsequencespecificDNAbindingbyp53followingtreatmentwithchemotherapeuticandDNAdamagingagents:R.B.Tishler,etal.;CancerRes.53,2212(1993)
TopoisomeraseII-etoposideinteractionsdirecttheformationofdrug-inducedenzyme-DNAcleavagecomplexes:D.A.Burden,etal.;J.Biol.Chem.271,29238(1996)
Celldeathinducedbytopoisomerase-targeteddrugs:morequestionsthananswers:S.H.Kaufmann;Biochim.Biophys.Acta1400,195(1998)(Review)
Etoposide:fourdecadesofdevelopmentofatopoisomeraseIIinhibitor:K.R.Hande;Eur.J.Cancer34,1514(1998)(Review)
Differentialregulationofp21waf-1/cip-1andMdm2byetoposide:etoposideinhibitsthep53-Mdm2autoregulatoryfeedbackloop:E.L.Arriola,etal.;Oncogene18,1081(1999)
Earlycaspaseactivationinleukemiccellssubjecttoetoposide-inducedG2-Marrest:evidenceofcommitmenttoapoptosisratherthanmitoticcelldeath:R.J.Sleiman&B.W.Stewart;Clin.CancerRes.6,3756(2000)
Orderingofceramideformation,caspaseactivation,andBax/Bcl-2expressionduringetoposide-inducedapoptosisinC6gliomacells:M.Sawada,etal.;CellDeathDiffer.7,761(2000)
Distinctpathwaysforstimulationofcytochromecreleasebyetoposide:J.D.Robertson,etal.;J.Biol.Chem.275,32438(2000)
DeacetylaseactivityassociateswithtopoisomeraseIIandisnecessaryforetoposide-inducedapoptosis:C.A.Johnson,etal.;J.Biol.Chem.276,4539(2001)
Etoposide:discoveryandmedicinalchemistry:P.Meresse,etal.;Curr.Med.Chem.11,2443(2004)(Review)
Etoposide,topoisomeraseIIandcancer:E.L.Baldwin&N.Osheroff;Curr.Med.Chem.AnticancerAgents5,363(2005)(Review)
ThedispersalofreplicationproteinsafterEtoposidetreatmentrequiresthecooperationofNbs1withtheataxiatelangiectasiaRad3-related/Chk1pathway:R.Rossi,etal.;CancerRes.66,1675(2006)
Cellularresponsetoetoposidetreatment:A.Montecucco&G.Biamonti;CancerLett.252,9(2007)(Review)
ChemomobilizationwithEtoposideisHighlyEffectiveinPatientswithMultipleMyelomaandOvercomestheEffectsofAgeandPriorTherapy:W.A.Wood,etal.;Biol.BloodMarrow.Transplant.17,141(2011)
Theagingeffectofchemotherapyonculturedhumanmesenchymalstemcells.S.Buttiglieri,etal.;Exp.Hematol.39,1171(2011)

对照品标准品，生物试剂盒，gibco胎牛血清，试剂采购网，中国试剂网，细胞因子试剂盒

Adipogen/Etoposide/AGCR135725100/5 x 100 mg